Skip to main content

On This Page

← AI Financial News

Oracle Corporation – 2026-02-02 - increase Confidence 6/10

2 min read $ORCL
Share

These articles are AI-generated summaries. Please check the original sources for full details.

ORCLOracle Corporation
$219.86-29.21 (-11.73%)
$328$273$218Aug 18Oct 2Nov 17
52W High: $328.3352W Low: $217.57Volume: 16.14M
NYSE
Prediction (2/16/2026):High: $345.72Low: $118.86Ref Price: $160.06
This chart shows historical data as of November 17, 2025. Not updated in real-time.

ORCL – Predicted Increase in Days/Weeks

Oracle’s stock price has fallen over 50% from its 52-week high, creating a potential oversold condition. A recent catalyst is Deutsche Bank reiterating a Buy rating with a $375 price target, implying over 130% upside from current levels.

Why This Matters

The stock’s severe decline from its peak, combined with a robust forward P/E of 20.2 based on strong TTM earnings, suggests the market may have overreacted to broader tech sector weakness. The upcoming earnings report on March 9th will be a critical near-term catalyst, but in the weeks leading up to it, positive analyst sentiment and the stock’s deeply discounted valuation could drive a relief rally. The market is beginning to refocus on Oracle’s solid financials—$15.4B in net income—and its strategic push into AI for regulated sectors, which may attract buyers seeking value in a beaten-down tech giant.

Key Insights

  • Valuation Gap: Stock price of $160.06 is 54% below its 52-week high of $345.72, trading at a forward P/E of 20.2.
  • News Impact: Deutsche Bank maintains a $375 price target (Buy rating), highlighting a massive disconnect between current price and analyst conviction.
  • Risk/Offset: Extremely high Debt/Equity of 432.5 and Beta of 1.63 indicate high financial leverage and volatility, which could amplify downside on negative news.

Practical Implications

  • Bull Case: Positive momentum from analyst upgrades and oversold technicals triggers a short-covering rally towards the $200 level ahead of earnings.
  • Bear Case: High debt burden and market skepticism about cloud/AI execution continue to weigh on sentiment, keeping the stock range-bound or pushing it lower.
  • Confidence: 6/10 – Strong analyst support and deep discount provide a floor, but high leverage and macro sensitivity limit near-term conviction.

Prediction: increase

Reference:

Continue reading

Next article

Regencell Bioscience – 2026-02-02 - Decrease Confidence 8/10

Related Content